IgA Nephropathy

A study examined whether COVID-19 independently affects the subsequent trajectory of kidney function in patients with IgAN.

A study analyzed the fecal microbiome of patients with IgA nephropathy, focusing on their immune response to microbiota.

Researchers examined the role of urinary sodium excretion and the progression of immunoglobulin A nephropathy (IgAN).

Vlado Perkovic spoke about findings from the FLOW, APPLAUSE-IgAN, and CREDENCE trials presented at ASN Kidney Week.

A study examined a possible link between IgA nephropathy (IgAN) and inflammatory skin diseases.

Could adding serum C3 and C4 levels to existing predictive models for IgA nephropathy (IgAN) improve their accuracy?

Could the systemic inflammatory response index (SIRI) be a useful measure of renal prognosis in IgA nephropathy (IgAN)?

Diffuse magnetic imaging resonance shows promise for evaluating clinical and pathological changes in patients with IgAN.

Purespring Therapeutics received $105M in Series B funding to develop gene therapies for kidney diseases, including IgAN.

Long-term results of a study of atacicept to treat IgA nephropathy (IgAN) will be presented at ASN Kidney Week.

Knowledge Hubs